Epigral Ltd shares dropped more than 6% in early trade on Monday after the company posted a steep decline in its second-quarter (Q2 FY2025) earnings. The sharp fall came as investors reacted to a 37% year-on-year (YoY) drop in net profit, reflecting pressure on margins and weaker operational performance.
The company reported a consolidated net profit of ₹51.2 crore, compared to ₹81.3 crore in the same quarter last year. Revenue from operations also declined 6.2% YoY, coming in at ₹587.3 crore, down from ₹626 crore in Q2 FY2024.
On the operational front, EBITDA fell 25.6% to ₹132 crore, as against ₹178 crore in the corresponding period last year. The EBITDA margin contracted by 600 basis points to 22.6% from 28.5%.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
